OTCMKTS:ALPMY Astellas Pharma (ALPMY) Stock Price, News & Analysis $11.00 +0.26 (+2.42%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$10.66▼$11.0050-Day Range$9.39▼$11.0052-Week Range$9.15▼$15.90Volume399,979 shsAverage Volume294,289 shsMarket Capitalization$19.90 billionP/E Ratio157.07Dividend Yield2.73%Price TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest Get Astellas Pharma alerts: Email Address Ad Behind the MarketsRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.Take these 4 steps to protect your retirement here. About Astellas Pharma Stock (OTCMKTS:ALPMY)Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.Read More ALPMY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALPMY Stock News HeadlinesJuly 26 at 11:41 AM | prnewswire.comAstellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction CancerJuly 26 at 11:39 AM | prnewswire.comAstellas Receives Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder CancerJuly 26, 2024 | Behind the Markets (Ad)Rare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.July 22, 2024 | markets.businessinsider.comAstellas, Osaka University To Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell TherapyJuly 22, 2024 | prnewswire.comAstellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell TherapyJuly 16, 2024 | americanbankingnews.comAstellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Down 10.5% in JuneMay 30, 2024 | prnewswire.comU.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATEMay 21, 2024 | msn.comAstellas Pharma partners with YASKAWA for innovative cell therapyJuly 26, 2024 | Behind the Markets (Ad)Rare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.May 21, 2024 | finance.yahoo.comAstellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics TechnologiesMay 8, 2024 | prnewswire.comAstellas Unveils New, State-of-the-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech CorridorMay 2, 2024 | msn.com7 Best Blue-Chip Dividend Stocks to BuyMay 1, 2024 | prnewswire.comAstellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyApril 25, 2024 | msn.comAstellas Pharma Non-GAAP EPS of ¥84.19, revenue of ¥1603.67B; initiates FY24 guidanceApril 23, 2024 | markets.businessinsider.comEuropean Commission Approves Astellas' Xtandi For Recurrent Early Prostate Cancer TreatmentApril 23, 2024 | prnewswire.comAstellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment SettingApril 22, 2024 | markets.businessinsider.comTakeda, Astellas, Sumitomo Mitsui Banking To Form JV For Incubation Of Early Drug Discovery ProgramsApril 15, 2024 | finance.yahoo.comU.S. Stocks Erase Early GainsSee More Headlines Receive ALPMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2023Today7/26/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:ALPMY CUSIPN/A CIK1446390 Webwww.astellas.com Phone(133) 244-3000FaxN/AEmployees14,484Year Founded1923Profitability EPS (Most Recent Fiscal Year)$0.07 Trailing P/E Ratio157.07 Forward P/E Ratio21.56 P/E GrowthN/ANet Income$118.07 million Net Margins1.20% Pretax MarginN/A Return on Equity5.85% Return on Assets2.85% Debt Debt-to-Equity Ratio0.31 Current Ratio0.91 Quick Ratio0.71 Sales & Book Value Annual Sales$11.11 billion Price / Sales1.79 Cash Flow$1.41 per share Price / Cash Flow7.81 Book Value$6.27 per share Price / Book1.75Miscellaneous Outstanding Shares1,809,660,000Free FloatN/AMarket Cap$19.90 billion OptionableNot Optionable Beta0.38 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Naoki Okamura BSc (Age 62)President, CEO & Director Comp: $961.41kMr. Atsushi KitamuraChief Financial OfficerNobue YasudaGeneral Manager of Finance & Accounting DepartmentMr. Yoshitsugu Shitaka Ph.D.Chief Scientific Officer & Senior Managing Executive OfficerMs. Catherine B. LevittGeneral CounselMr. Katsuyoshi Sugita (Age 57)Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director Mr. Stig OgataVice President of Corporate CommunicationsMs. Collette Taylor (Age 61)Senior Vice President of Human Resources Ms. Tatjana DragovicSenior VP and Head of Ethics & ComplianceMr. Nobuaki TanakaPresident of Japan Commercial & Senior Corporate ExecutiveMore ExecutivesKey CompetitorsTakeda PharmaceuticalNYSE:TAKAlnylam PharmaceuticalsNASDAQ:ALNYBayer AktiengesellschaftOTCMKTS:BAYRYMerck KGaAOTCMKTS:MKGAFTeva Pharmaceutical IndustriesNYSE:TEVAView All Competitors ALPMY Stock Analysis - Frequently Asked Questions How have ALPMY shares performed this year? Astellas Pharma's stock was trading at $11.90 on January 1st, 2024. Since then, ALPMY stock has decreased by 7.6% and is now trading at $10.9950. View the best growth stocks for 2024 here. How were Astellas Pharma's earnings last quarter? Astellas Pharma Inc. (OTCMKTS:ALPMY) posted its quarterly earnings results on Wednesday, November, 1st. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by $0.18. The firm earned $2.71 billion during the quarter. Astellas Pharma had a trailing twelve-month return on equity of 5.85% and a net margin of 1.20%. When did Astellas Pharma's stock split? Astellas Pharma shares split on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly created shares were distributed to shareholders after the closing bell on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split. Does Astellas Pharma have any subsidiaries? The following companies are subsidiaries of Astellas Pharma: Iota Biosciences, Nanna Therapeutics, Xyphos, Audentes Therapeutics, Potenza Therapeutics, Quethera, Universal Cells Inc., and others. How do I buy shares of Astellas Pharma? Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ALPMY) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astellas Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astellas Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALPMY Stock Alerts